Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Surgery Partners's accounts receivables for the quarter that ended in Jun. 2026 was €535 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Surgery Partners's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 66.28.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Surgery Partners's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was €-37.47.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Surgery Partners's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Surgery Partners's accounts receivable are only considered to be worth 75% of book value:
Surgery Partners's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Surgery Partners Accounts Receivable Related Terms
Surgery Partners Accounts Receivable Historical Data
* Premium members only.
The historical data trend for Surgery Partners's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgery Partners (FRA:1SP) has a Accounts Receivable of €535 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Surgery Partners and its competitors.
Is Surgery Partners' Accounts Receivable too high?
Surgery Partners' current Accounts Receivable is €535 Mil. Overall, Surgery Partners has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Surgery Partners' Accounts Receivable compare to SNDA and ASTH?
Surgery Partners' Accounts Receivable of €535 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Healthcare Providers & Services company?
A good Accounts Receivable depends on the Healthcare Providers & Services industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Surgery Partners and its competitors. Surgery Partners's current Accounts Receivable is €535 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgery Partners stock overvalued right now?
Based on GuruFocus' analysis, Surgery Partners (FRA:1SP) is currently considered Possible Value Trap. The stock's GF Value™ is €21.02, compared to a current price of €12.10 — trading 42.4% below its estimated fair value. The current Accounts Receivable is €535 Mil. Surgery Partners' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Surgery Partners (FRA:1SP), the current Accounts Receivable is €535 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgery Partners (FRA:1SP) Overvalued in 2026?
Based on GuruFocus' analysis, Surgery Partners stock appears to be undervalued.
The current stock price of €12.10 is trading 42.4% below its estimated GF Value™ of €21.02.
GuruFocus considers Surgery Partners to be Possible Value Trap.
Key valuation signals for FRA:1SP:
Accounts Receivable: €535 Mil
GF Value™: €21.02 vs. price of €12.10 (42.4% below fair value)
No single metric tells the full story. See the FRA:1SP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
61GF Score
Get the complete analysis for FRA:1SP
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1SP has been successfully added to your 
